PFS Not Associated With 1-Year Depth of Response to Ibrutinib in Chronic Lymphocytic Leukemia
Researchers sought to determine whether there was a difference in PFS based on depth of response with ibrutinib at 1 year in patients with CLL.
All articles by Lauren Dembeck, PhD
Ruxolitinib Monotherapy May Be an Effective Treatment Option in Some Children With Hemophagocytic Lymphohistiocytosis
The researchers evaluated the safety and efficacy of ruxolitinib as a first-line agent for pediatric HLH.
Second SARS-CoV-2 Vaccination Improves Antibody Responses in Patients With Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria
Researchers sought to determine whether patients with aplastic anemia and PNH would benefit from a second SARS-CoV-2 vaccination.
Targeted Radiotherapy Remains Important in Pediatric Hodgkin Lymphoma With Slow Early Response to Chemotherapy
Researchers sought to assess the importance of radiotherapy in pediatric patients with early‐stage low-risk classical Hodgkin lymphoma.
Response-Adapted Nivolumab Salvage Therapy Safe and Effective in Classical Hodgkin Lymphoma
Researchers sought to determine whether response-adapted sequential salvage therapy would be effective in patients with relapsed/refractory classical Hodgkin lymphoma.
OVID Findings Do Not Support Routine Use of Anticoagulant in Outpatients With COVID-19
Researchers sought to determine whether thromboprophylaxis with enoxaparin would reduce early hospitalizations and deaths among outpatients with symptomatic COVID-19.
Real-World Treatment Outcomes, Roles of Transplantation and Maintenance Rituximab in Mantle Cell Lymphoma
Researchers sought to determine the role and utilization of ASCT in younger patients with MCL.
Study Finds Racial Disparities in Cancer-Associated Thrombosis
Researchers sought to determine whether the incidence of CAT was different across designated racial groups.
CD24 Expression on Plasma Cells Is a Prognostic Marker for Survival in Multiple Myeloma
Researchers sought to determine whether elevated CD24 expression on plasma cells was a prognostic factor in multiple myeloma.
Khorana Score Unable to Stratify Patients With Certain Cancer Subtypes by Risk of Venous Thromboembolism
Researchers sought to determine whether the Khorana score would be able to risk-stratify patients according to the 6-month risk of incident VTE.
- Loading...
Loading...
Next post in Thrombotic Disorders
Loading... 
Loading...